{
    "clinical_study": {
        "@rank": "13425", 
        "arm_group": [
            {
                "arm_group_label": "Dabigatran"
            }, 
            {
                "arm_group_label": "Warfarin"
            }
        ], 
        "brief_summary": {
            "textblock": "This cohort study is the sequential expansion of the comparative effectiveness study of oral\n      anticoagulants and plans to identify initiators of oral anticoagulants using electronic\n      claims data from a commercial insurance database to quantify associations between\n      anticoagulant choice (warfarin and dabigatran) and the occurrence of selected outcomes in\n      patients with non-valvular atrial fibrillation at risk for stroke."
        }, 
        "brief_title": "Sequential Expansion of Comparative Effectiveness of Anticoagulants", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  A recorded diagnosis of atrial fibrillation.\n\n          -  Initiation of anticoagulant medication (dabigatran (or other new oral anticoagulants\n             as they become available) or warfarin).\n\n          -  At least 18 years of age on the date of anticoagulant initiation.\n\n          -  CHA2DS2-VASc score at least 1\n\n        Exclusion criteria:\n\n          -  Patients with missing or ambiguous age or sex information.\n\n          -  Patients with evidence of valvular disease.\n\n          -  Patients with less than 12 months enrolment preceding the date of anticoagulant\n             initiation\n\n          -  Patients with  a dispensing of any oral anticoagulant during the 12 months preceding\n             the date of anticoagulant initiation\n\n          -  Patients with a nursing home stay during the 12 months preceding the date of\n             anticoagulant initiation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients 18 years of age and older with non-valvular AF initiating oral anticoagulation\n        therapy"
            }
        }, 
        "enrollment": {
            "#text": "120000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081807", 
            "org_study_id": "1160.207"
        }, 
        "intervention_browse": {
            "mesh_term": "Anticoagulants"
        }, 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }, 
                "name": "1160.207.1 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Sequential Expansion of Comparative Effectiveness of Oral Anticoagulants: A Cohort Study", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Stroke", 
                "safety_issue": "No", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Major bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081807"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Stroke or systemic embolism", 
                "safety_issue": "No", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Systemic embolism", 
                "safety_issue": "No", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Ischemic stroke", 
                "safety_issue": "No", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Hemorrhagic stroke", 
                "safety_issue": "No", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Stroke uncertain classification", 
                "safety_issue": "No", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Major intracranial bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Major extracranial bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Major gastrointestinal bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Transient Ischemic Attack", 
                "safety_issue": "No", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Myocardial infarction", 
                "safety_issue": "No", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Venous Thromboembolism", 
                "safety_issue": "No", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Deep vein thrombosis", 
                "safety_issue": "No", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Pulmonary Embolism", 
                "safety_issue": "No", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Major upper gastrointestinal bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Major lower gastrointestinal bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Major urogenital bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }, 
            {
                "measure": "Other major bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "From treatment initiation until end of follow-up; up to 62 months"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}